This disclosure relates to Compound 1,(Compound 1)pharmaceutically acceptable salts, or pharmaceutically acceptable compositions thereof, for the treatment of CNS related disorders,e.g.,tremor,e.g.,essential tremor； depression； and anxiety disorder, and methods for improving the effectiveness of the administration of Compound 1 for treating said CNS related disorders. The disclosure also relates to methods of increasing the bioavailability of a Compound 1 or pharmaceutically acceptable salts, or pharmaceutically acceptable compositions thereof.本揭示內容係關於化合物1，(化合物1)其醫藥上可接受之鹽或醫藥上可接受之組合物，其用於治療CNS相關病症，例如震顫，例如自發性震顫；抑鬱症；及焦慮症；以及用於改良化合物1之投藥效力，以治療該等CNS相關病症之方法。本揭示內容亦係關於提高化合物1或其醫藥上可接受之鹽或醫藥上可接受之組合物之生體可用率之方法。
